Regulus Therapeutics (United States)

Regulus Therapeutics (United States)

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2024. Read More.


Open Access Percentage

55%


Total
Publications

169


Total Open
Publications

93


Total
Citations

21K


Open Access
Percentage

55%


Total
Publications

169


Total Open
Publications

93


Total
Citations

21K

Wikipedia

Website

download

Breakdown

9% 31% 15% 45%

Publisher Open

9%

Both

31%

Other Platform Open

15%

Closed

45%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

024681012141618202224Total Publications
20082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

28%OA Journal

OA Journal 28%

19

Hybrid 27%

18

No Guarantees 45%

30

Other Platform Open

Domain 90%

70

Institution 24%

19

Public 21%

16

Other Internet 15%

12

Preprint 6%

5

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
70
Europe PMC
Domain
53
DOI
Other Internet
27
Semantic Scholar
Public
10
Figshare
Public
9
California Digital Library - eScholarship
Other Internet
6
California Institute of Technology - CaltechAUTHORS
Institution
5
bioRxiv
Preprint
5
Harvard University - Digital Access to Scholarship at Harvard (DASH)
Institution
4
University College London - UCL Discovery
Institution
2
1 / 3

Data updated 13 February 2025

Share

Share

Share